Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers
Latest Information Update: 30 Jan 2023
At a glance
- Drugs Selpercatinib (Primary)
- Indications Carcinoma; Squamous cell cancer; Thyroid cancer
- Focus Therapeutic Use
- 13 May 2021 One more primary efficacy end-point of Tumor response has been added.
- 02 Apr 2021 Status changed from not yet recruiting to recruiting.
- 23 Feb 2021 New trial record